Context Therapeutics Announces Positive Interim Phase 1 Data for CTIM-76 in Ovarian Cancer
On June 15, 2026, Context Therapeutics announced positive interim Phase 1a clinical data for CTIM-76, its Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, in patients with advanced platinum-resistant ovarian cancer (PROC). In heavily pretreated patients (median of 7 prior lines), CTIM-76 demonstrated a 29% confirmed overall response rate (ORR) and a 57% disease control rate (DCR) at active dose levels (140Β΅g to 280Β΅g). The safety profile was favorable, with cytokine release syndrome (CRS) limited to Grade 1 in only 11% of PROC patients, potentially supporting outpatient dosing. Preliminary pharmacokinetic data supports the exploration of an every-three-week (Q3W) dosing schedule to mitigate T cell exhaustion, with evaluation planned for 2H 2026. CTIM-76 has also received FDA Fast Track Designation. Additionally, the company provided updates on CT-95 (Mesothelin x CD3) and CT-202 (Nectin-4 x CD3), with preliminary Phase 1a data for CT-95 expected in September 2026 and a Phase 1 first patient dose for CT-202 anticipated in Q3 2026. Context reports a cash runway into mid-2027.